CD70 CAR-T by UTC Therapeutics for Burkitt Lymphoma: Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and is currently in the Phase II in clinical pathway.

Related Posts

Opinion: The misguided reason why providers aren’t pres...

Jan 6, 2024

FDA advisers endorse updating Covid vaccines to target ...

Jun 16, 2023

FDA accepts resubmission of Ardelyx’s NDA for XPHOZAH

May 18, 2023